Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730821 · ClinicalTrials.gov registry record · Phase 1
Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 4
- Study locations
NCT00730821: Completed Phase 1 study of Neoplasms, sponsored by Boehringer Ingelheim.
NCT00730821 is a Phase 1 study of Neoplasms that has completed, run by Boehringer Ingelheim. The registered enrollment target is 28 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00730821, a Phase 1 study of Neoplasms, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule. Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and BIBW 2992, and if data allow the determination of the pharmacokinetic influence of BIBW 2992 on BIBF 1120 and vice versa.
Conditions Studied
Interventions
- DRUG BIBW 2992
- DRUG BIBF 1120
Study Locations (4)
Arizona
- 1239.1.3 Boehringer Ingelheim Investigational Site - Scottsdale
Florida
- 1239.1.1 Boehringer Ingelheim Investigational Site - Tampa
Michigan
- 1239.1.2 Boehringer Ingelheim Investigational Site - Detroit
Nebraska
- 1239.1.4 Boehringer Ingelheim Investigational Site - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2007-01 |
| Phase | Phase 1 |
What the finished NCT00730821 record still lists
NCT00730821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which BIBW 2992 is the first listed.
NCT00730821 reports a single indexed study location in Arizona, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT00730821 about?
NCT00730821 is a clinical study titled "Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors". The primary objective of this trial is to determine the MTD of the combination of BIBW 2992/BIBF 1120 therapy administered concomitantly in a 28-day cycle schedule. Secondary objectives are the collection of antitumor efficacy data, the determination of pharmacokinetic parameters of BIBF 1120 and B...
What is the current status of trial NCT00730821?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2007-01.
What conditions does trial NCT00730821 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT00730821?
The interventions under investigation include: BIBW 2992 (DRUG), BIBF 1120 (DRUG).
Who is sponsoring clinical trial NCT00730821?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00730821 being conducted?
This trial has 4 study locations across Arizona, Florida, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00730821's enrollment target sits among peer trials
28 140th of 158 higher than 19 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia